Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Drop in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 104,240 shares, a decline of 59.8% from the January 29th total of 259,453 shares. Based on an average trading volume of 102,383 shares, the short-interest ratio is currently 1.0 days. Approximately 1.6% of the company’s stock are sold short. Approximately 1.6% of the company’s stock are sold short. Based on an average trading volume of 102,383 shares, the short-interest ratio is currently 1.0 days.

Calidi Biotherapeutics Stock Performance

CLDI opened at $0.79 on Friday. The stock has a fifty day moving average price of $1.00 and a 200 day moving average price of $1.46. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.12 and a quick ratio of 2.12. Calidi Biotherapeutics has a 1 year low of $0.72 and a 1 year high of $19.20.

Institutional Investors Weigh In On Calidi Biotherapeutics

Several large investors have recently made changes to their positions in the company. DRW Securities LLC bought a new position in Calidi Biotherapeutics during the fourth quarter valued at approximately $173,000. Virtu Financial LLC acquired a new position in shares of Calidi Biotherapeutics during the 4th quarter worth $25,000. Warberg Asset Management LLC acquired a new position in shares of Calidi Biotherapeutics during the 3rd quarter worth $28,000. Finally, Geode Capital Management LLC raised its holdings in shares of Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares in the last quarter. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.